The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Volynets G.V.

Veltishchev Research Clinical Institute of Pediatrics and Pediatric Surgery — Pirogov Russian National Research Medical University;
Pirogov Russian National Research Medical University

Khavkin A.I.

Research and Clinical Institute of Childhood

Skvortsova T.A.

Veltishchev Research Clinical Institute of Pediatrics and Pediatric Surgery — Pirogov Russian National Research Medical University;
Pirogov Russian National Research Medical University;
Morozovskaya Children’s City Clinical Hospital

Nikitin A.V.

Veltishchev Research Clinical Institute of Pediatrics and Pediatric Surgery — Pirogov Russian National Research Medical University;
Pirogov Russian National Research Medical University;
Morozovskaya Children’s City Clinical Hospital

Peroxisomes and their role in pediatric diseases

Authors:

Volynets G.V., Khavkin A.I., Skvortsova T.A., Nikitin A.V.

More about the authors

Journal: Russian Journal of Evidence-Based Gastroenterology. 2025;14(1): 91‑103

DOI: 10.17116/dokgastro20251401191

Read: 4267 times

Download PDF (RU)
Contact the author
Table of contents

PEROXISOMES AND THEIR ROLE IN PEDIATRIC DISEASES
PEROXISOMES AND THEIR ROLE IN PEDIATRIC DISEASES

To cite this article:

Volynets GV, Khavkin AI, Skvortsova TA, Nikitin AV. Peroxisomes and their role in pediatric diseases. Russian Journal of Evidence-Based Gastroenterology. 2025;14(1):91‑103. (In Russ.)
https://doi.org/10.17116/dokgastro20251401191

Подписка 2026 Доказательная гастроэнтерология (Russian Journal of Evidence-Based Gastroenterology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Combination of gothic palate and pes cavus — pattern or coincidence?. Russian Journal of Stomatology. 2025;(3):74-80
Abstract:

Peroxisomes are specialized single-membrane organelles that play a key role in lipid metabolism, detoxification, and redox regulation. Disruptions in their biogenesis and function lead to severe inherited diseases, including Zellweger spectrum disorders and rhizomelic chondrodysplasia punctata. Despite significant advances in peroxisomal research, their involvement in various pathologies, including viral infections and immune disorders, remains insufficiently studied.

OBJECTIVE:

To analyze current data on the structure, functions, and interactions of peroxisomes with other organelles, their role in human metabolism, immune processes, and the pathogenesis of diseases associated with peroxisomal protein defects.

KEY POINTS

Peroxisomes participate in fatty acid oxidation, ether lipid biosynthesis, and reactive oxygen species metabolism. Their interactions with mitochondria, lysosomes, and the endoplasmic reticulum play a crucial role in cellular homeostasis. Peroxisomal metabolic dysfunction is linked not only to genetic diseases but also to altered immune responses, viral infections, and neurodegenerative processes. This review presents contemporary insights into the mechanisms underlying peroxisomal disorders and potential therapeutic approaches.

CONCLUSION

Peroxisomal defects represent complex systemic disorders requiring a multidisciplinary approach. Modern molecular technologies enable the identification of novel disease mechanisms and the development of personalized treatment strategies. Further research is needed to clarify their role in immune regulation and infectious pathology.

Keywords:

peroxisomes
lipid metabolism
genetic diseases
immunomodulation
Zellweger syndrome

Authors:

Volynets G.V.

Veltishchev Research Clinical Institute of Pediatrics and Pediatric Surgery — Pirogov Russian National Research Medical University;
Pirogov Russian National Research Medical University

Khavkin A.I.

Research and Clinical Institute of Childhood

Skvortsova T.A.

Veltishchev Research Clinical Institute of Pediatrics and Pediatric Surgery — Pirogov Russian National Research Medical University;
Pirogov Russian National Research Medical University;
Morozovskaya Children’s City Clinical Hospital

Nikitin A.V.

Veltishchev Research Clinical Institute of Pediatrics and Pediatric Surgery — Pirogov Russian National Research Medical University;
Pirogov Russian National Research Medical University;
Morozovskaya Children’s City Clinical Hospital

Received:

09.12.2024

Accepted:

21.01.2025

Close metadata

References:

  1. Wanders RJ, Waterham HR. Biochemistry of mammalian peroxisomes revisited. Annual Review of Biochemistry. 2006;75:295-332.  https://doi.org/10.1146/annurev.biochem.74.082803.133329
  2. Wanders RJA, Baes M, Ribeiro D, Ferdinandusse S, Waterham HR. The physiological functions of human peroxisomes. Physiological Reviews. 2023;103(1):957-1024. https://doi.org/10.1152/physrev.00051.2021
  3. Di Cara F, Savary S, Kovacs WJ, Kim P, Rachubinski RA. The peroxisome: an up-and-coming organelle in immunometabolism. Trends in Cell Biology. 2023;33(1):70-86.  https://doi.org/10.1016/j.tcb.2022.06.001
  4. Lodhi IJ, Wei X, Yin L, Feng C, Adak S, Abou-Ezzi G, Hsu FF, Link DC, Semenkovich CF. Peroxisomal lipid synthesis regulates inflammation by sustaining neutrophil membrane phospholipid composition and viability. Cell Metabolism. 2015;21(1):51-64.  https://doi.org/10.1016/j.cmet.2014.12.002
  5. Di Cara F, Sheshachalam A, Braverman NE, Rachubinski RA, Simmonds AJ. Peroxisome-mediated metabolism is required for immune response to microbial infection. Immunity. 2018;48(4):832-833.  https://doi.org/10.1016/j.immuni.2018.03.035
  6. Ferreira AR, Marques M, Ribeiro D. Peroxisomes and innate immunity: antiviral response and beyond. International Journal of Molecular Sciences. 2019;20(15):3795. https://doi.org/10.3390/ijms20153795
  7. Meghnem D, Leong E, Pinelli M, Marshall JS, Di Cara F. Peroxisomes regulate cellular free fatty acids to modulate mast cell TLR2, TLR4, and IgE-mediated activation. Frontiers in Cell and Developmental Biology. 2022;10:856243. https://doi.org/10.3389/fcell.2022.856243
  8. Nath AS, Parsons BD, Makdissi S, Chilvers RL, Mu Y, Weaver CM, Euodia I, Fitze KA, Long J, Scur M, Mackenzie DP, Makrigiannis AP, Pichaud N, Boudreau LH, Simmonds AJ, Webber CA, Derfalvi B, Hammon Y, Rachubinski RA, Di Cara F. Modulation of the cell membrane lipid milieu by peroxisomal beta-oxidation induces Rho1 signaling to trigger inflammatory responses. Cell Reports. 2022;38(9):110433. https://doi.org/10.1016/j.celrep.2022.110433
  9. Vijayan V, Srinu T, Karnati S, Garikapati V, Linke M, Kamalyan L, Mali SR, Sudan K, Kollas A, Schmid T, Schulz S, Spengler B, Weichhart T, Immenschuh S, Baumgart-Vogt E. A new immunomodulatory role for peroxisomes in macrophages activated by the TLR4 ligand lipopolysaccharide. Journal of Immunology. 2017;198(6):2414-2425. https://doi.org/10.4049/jimmunol.1601596
  10. Muri J, Corak B, Matsushita M, Baes M, Kopf M. Peroxisomes are critical for the development and maintenance of B1 and marginal zone B cells but dispensable for follicular B cells and T cells. Journal of Immunology. 2022;208(4):839-850.  https://doi.org/10.4049/jimmunol.2100518
  11. Hoepfner D, Schildknegt D, Braakman I, Philippsen P, Tabak HF. Contribution of the endoplasmic reticulum to peroxisome formation. Cell. 2005;122(1):85-95.  https://doi.org/10.1016/j.cell.2005.04.025
  12. Schrader M, Costello JL, Godinho LF, Azadi AS, Islinger M. Proliferation and fission of peroxisomes — An update. Biochimica et Biophysica Acta (BBA) — Molecular Cell Research. 2016;1863(5):971-983.  https://doi.org/10.1016/j.bbamcr.2015.09.024
  13. Parsons BD, Medina-Luna D, Scur M, Pinelli M, Gamage GS, Chilvers RA, Hamon Y, Ahmed IHI, Savary S, Makrigiannis AP, Braverman NE, Rodriguez-Alcazar JF, Latz E, Karakach TK, Di Cara F. Peroxisome deficiency underlies failures in hepatic immune cell development and antigen presentation in a severe Zellweger disease model. Cell Reports. 2024;43(2):113744. https://doi.org/10.1016/j.celrep.2024.113744
  14. Thoms S. Import of proteins into peroxisomes: piggybacking to a new home away from home. Open Biology. 2015;5(11):150148. https://doi.org/10.1098/rsob.150148
  15. Schrader TA, Carmichael RE, Islinger M, Costello JL, Hacker C, Bonekamp NA, Weishaupt JH, Andersen PM, Schrader M. PEX11β and FIS1 cooperate in peroxisome division independently of mitochondrial fission factor. Journal of Cell Science. 2022;135(13):jcs259924. https://doi.org/10.1242/jcs.259924
  16. Williams C, Opalinski L, Landgraf C, Costello J, Schrader M, Krikken AM, Knoops K, Kram AM, Volkmer R, van der Klei IJ. The membrane remodeling protein Pex11p activates the GTPase Dnm1p during peroxisomal fission. Proceedings of the National Academy of Sciences of the United States of America. 2015; 112(20):6377-6382. https://doi.org/10.1073/pnas.1418736112
  17. Motley AM, Ward GP, Hettema EH. Dnm1p-dependent peroxisome fission requires Caf4p, Mdv1p and Fis1p. Journal of Cell Science. 2008;121(Pt 10):1633-1640. https://doi.org/10.1242/jcs.026344
  18. Sugiura A, Mattie S, Prudent J, McBride HM. Newly born peroxisomes are a hybrid of mitochondrial and ER-derived pre-peroxisomes. Nature. 2017;542(7640):251-254.  https://doi.org/10.1038/nature21375
  19. Fang Y, Morrell JC, Jones JM, Gould SJ. PEX3 functions as a PEX19 docking factor in the import of class I peroxisomal membrane proteins. Journal of Cell Biology. 2004;164(6):863-875.  https://doi.org/10.1083/jcb.200311131
  20. Eberhart T, Kovacs WJ. Pexophagy in yeast and mammals: an update on mysteries. Histochemistry and Cell Biology. 2018;150(5): 473-488.  https://doi.org/10.1007/s00418-018-1724-3
  21. Hossain MS, Mawatari S, Fujino T. Biological functions of plasmalogens. Advances in Experimental Medicine and Biology. 2020; 1299:171-193.  https://doi.org/10.1007/978-3-030-60204-8_13
  22. Argyriou C, D’Agostino MD, Braverman N. Peroxisome biogenesis disorders. Translational Science of Rare Diseases. 2016;1(2):111-144.  https://doi.org/10.3233/TRD-160003
  23. Chang CL, Weigel AV, Ioannou MS, Pasolli HA, Xu CS, Peale DR, Shtengel G, Freeman M, Hess HF, Blackstone C, Lippincott-Schwartz J. Spastin tethers lipid droplets to peroxisomes and directs fatty acid trafficking through ESCRT-III. Journal of Cell Biology. 2019;218(8):2583-2599. https://doi.org/10.1083/jcb.201902061
  24. Chu B-B, Liao Y-C, Qi W, Xie C, Du X, Wang J, Yang H, Miao H-H, Li B-L, Song B-L. Cholesterol transport through lysosome-peroxisome membrane contacts. Cell. 2015;161(2):291-306.  https://doi.org/10.1016/j.cell.2015.02.019
  25. Dixit E, Boulant S, Zhang Y, Lee AS, Odendall C, Shum B, Hacohen N, Chen ZJ, Whelan SP, Fransen M, Nibert ML, Superti-Furga G, Kagan JC. Peroxisomes are signaling platforms for antiviral innate immunity. Cell. 2010;141(4):668-681.  https://doi.org/10.1016/j.cell.2010.04.018
  26. Odendall C, Dixit E, Stavru F, Bierne H, Franz KM, Durbin AF, Boulant S, Gehrke L, Cossart P, Kagan JC. Diverse intracellular pathogens activate type III interferon expression from peroxisomes. Nature Immunology. 2014;15(8):717-726.  https://doi.org/10.1038/ni.2915
  27. Bender S, Reuter A, Eberle F, Einhorn E, Binder M, Bartenschlager R. Activation of type I and III interferon response by mitochondrial and peroxisomal MAVS and inhibition by hepatitis C virus. PLoS Pathogens. 2015;11(11):e1005264. https://doi.org/10.1371/journal.ppat.1005264
  28. Gürtler C, Bowie AG. Innate immune detection of microbial nucleic acids. Trends in Microbiology. 2013;21(8):413-420.  https://doi.org/10.1016/j.tim.2013.04.004
  29. Fujiki Y, Abe Y, Imoto Y, Tanaka AJ, Okumoto K, Honsho M, Tamura S, Miyata N, Yamashita T, Chung WK, Kuroiwa T. Recent insights into peroxisome biogenesis and associated diseases. Journal of Cell Science. 2020;133(9):jcs236943. https://doi.org/10.1242/jcs.236943
  30. Smith JJ, Aitchison JD. Peroxisomes take shape. Nature Reviews Molecular Cell Biology. 2013;14(12):803-817.  https://doi.org/10.1038/nrm3700
  31. Buchert R, Tawamie H, Smith C, Uebe S, Innes AM, Al Hallak B, Ekici AB, Sticht H, Schwarze B, Lamont RE, Parboosingh JS, Bernier FP, Abou Jamra R. A peroxisomal disorder of severe intellectual disability, epilepsy, and cataracts due to fatty acyl-CoA reductase 1 deficiency. American Journal of Human Genetics. 2014; 95(5):602-610.  https://doi.org/10.1016/j.ajhg.2014.10.003
  32. Barøy T, Koster J, Strømme P, Ebberink MS, Misceo D, Ferdinandusse S, Holmgren A, Hughes T, Merckoll E, Westvik J, Woldseth B, Walter J, Wood N, Tvedt B, Stadskleiv K, Wanders RJ, Waterham HR, Frengen E. A novel type of rhizomelic chondrodysplasia punctata, RCDP5, is caused by loss of the PEX5 long isoform. Human Molecular Genetics. 2015;24(20):5845-5854. https://doi.org/10.1093/hmg/ddv305
  33. Duker AL, Niiler T, Kinderman D, Schouten M, Poll-The BT, Braverman N, Bober MB. Rhizomelic chondrodysplasia punctata morbidity and mortality, an update. American Journal of Medical Genetics Part A. 2020;182(3):579-583.  https://doi.org/10.1002/ajmg.a.61413
  34. Bams-Mengerink AM, Koelman JH, Waterham H, Barth PG, Poll-The BT. The neurology of rhizomelic chondrodysplasia punctata. Orphanet Journal of Rare Diseases. 2013;8:174.  https://doi.org/10.1186/1750-1172-8-174
  35. Duker AL, Niiler T, Eldridge G, Brereton NH, Braverman NE, Bober MB. Growth charts for individuals with rhizomelic chondrodysplasia punctata. American Journal of Medical Genetics Part A. 2017;173(1):108-113.  https://doi.org/10.1002/ajmg.a.37961
  36. Itzkovitz B, Jiralerspong S, Nimmo G, Loscalzo M, Horovitz DD, Snowden A, Moser A, Steinberg S, Braverman N. Functional characterization of novel mutations in GNPAT and AGPS, causing rhizomelic chondrodysplasia punctata (RCDP) types 2 and 3. Human Mutation. 2012;33(1):189-197.  https://doi.org/10.1002/humu.21623
  37. Luisman T, Smith T, Ritchie S, Malone KE. Genetic epidemiology approach to estimating birth incidence and current disease prevalence for rhizomelic chondrodysplasia punctata. Orphanet Journal of Rare Diseases. 2021;16(1):300.  https://doi.org/10.1186/s13023-021-01889-z
  38. Braverman NE, D’Agostino MD, Maclean GE. Peroxisome biogenesis disorders: Biological, clinical and pathophysiological perspectives. Developmental Disabilities Research Reviews. 2013;17(3):187-196.  https://doi.org/10.1002/ddrr.1113
  39. Lucaccioni L, Righi B, Cingolani GM, Lugli L, Della Casa E, Torcetta F, Iughetti L, Berardi A. Overwhelming sepsis in a neonate affected by Zellweger syndrome due to a compound heterozygosis in PEX6 gene: a case report. BMC Medical Genetics. 2020;21(1):229.  https://doi.org/10.1186/s12881-020-01175-y
  40. Fazi C, Lodi L, Magi L, Canessa C, Giovannini M, Pelosi C, Pochiero F, Procopio E, Donati MA, Azzari C, Ricci S. Case Report: Zellweger Syndrome and Humoral Immunodeficiency: The Relevance of Newborn Screening for Primary Immunodeficiency. Frontiers in Pediatrics. 2022;10:852943. https://doi.org/10.3389/fped.2022.852943
  41. Fletcher JM, Jordan MA, Snelgrove SL, Slattery RM, Dufour FD, Kyparissoudis K, Besra GS, Godfrey DI, Baxter AG. Congenic analysis of the NKT cell control gene Nkt2 implicates the peroxisomal protein Pxmp4. Journal of Immunology. 2008;181(5):3400-3412. https://doi.org/10.4049/jimmunol.181.5.3400
  42. Liang Y, Kaneko K, Xin B, Lee J, Sun X, Zhang K, Feng GS. Temporal analyses of postnatal liver development and maturation by single-cell transcriptomics. Developmental Cell. 2022;57(3):398-414.e5. PMID: 35134346; PMCID: PMC8842999. https://doi.org/10.1016/j.devcel.2022.01.004
  43. Nakagaki BN, Mafra K, de Carvalho É, Lopes ME, Carvalho-Gontijo R, de Castro-Oliveira HM, Campolina-Silva GH, de Miranda CDM, Antunes MM, Silva ACC, Diniz AB, Alvarenga DM, Lopes MAF, de Souza Lacerda VA, Mattos MS, Araújo AM, Vidigal PVT, Lima CX, Mahecha GAB, Madeira MFM, Fernandes GR, Nogueira RF, Moreira TG, David BA, Rezende RM, Menezes GB. Immune and metabolic shifts during neonatal development reprogram liver identity and function. Journal of Hepatology. 2018;69(6):1294-1307. https://doi.org/10.1016/j.jhep.2018.08.018
  44. Cardoso P, Amaral ME, Lemos S, Garcia P. Zellweger syndrome with severe malnutrition, immunocompromised state and opportunistic infections. BMJ Case Reports. 2016;2016:bcr2015214283. https://doi.org/10.1136/bcr-2015-214283
  45. Althonaian N, Alsultan A, Morava E, Alfadhel M. Secondary hemophagocytic syndrome associated with COG6 gene defect: Report and review. JIMD Reports. 2018;42:105-111.  https://doi.org/10.1007/8904_2018_88
  46. Barnabei L, Laplantine E, Mbongo W, Rieux-Laucat F, Weil R. NF-kappaB: At the borders of autoimmunity and inflammation. Frontiers in Immunology. 2021;12:716469. https://doi.org/10.3389/fimmu.2021.716469
  47. Biro M, Munoz MA, Weninger W. Targeting Rho-GTPases in immune cell migration and inflammation. British Journal of Pharmacology. 2014;171(24):5491-5506. https://doi.org/10.1111/bph.12658
  48. Bros M, Haas K, Moll L, Grabbe S. RhoA as a key regulator of innate and adaptive immunity. Cells. 2019;8(7):733.  https://doi.org/10.3390/cells8070733
  49. Chen K, Zhang N, Shao JB, Li H, Li J, Xi JM, Xu WH, Jiang H. Allogeneic hematopoietic stem cell transplantation for PEX1-related Zellweger spectrum disorder: A case report and literature review. Frontiers in Pediatrics. 2021;9:672187. https://doi.org/10.3389/fped.2021.672187
  50. Shapiro E, Krivit W, Lockman L, Jambaqué I, Peters C, Cowan M, Harris R, Blanche S, Bordigoni P, Loes D, Ziegler R, Crittenden M, Ris D, Berg B, Cox C, Moser H, Fischer A, Aubourg P. Long-term effect of bone marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. The Lancet. 2000;356(9231):713-718.  https://doi.org/10.1016/S0140-6736(00)02629-5
  51. Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. The gut-liver axis and the intersection with the microbiome. Nature Reviews Gastroenterology and Hepatology. 2018;15(7):397-411.  https://doi.org/10.1038/s41575-018-0011-z
  52. Kawakami K, Matsuo H, Kajitani N, Yamada T, Matsumoto KI. Comparison of survival rates in four inbred mouse strains under different housing conditions: Effects of environmental enrichment. Experimental Animals. 2022;71(2):150-160.  https://doi.org/10.1538/expanim.21-0118
  53. Gola A, Dorrington MG, Speranza E, Sala C, Shih RM, Radtke AJ, Wong HS, Baptista AP, Hernandez JM, Castellani G, Fraser IDC, Germain RN. Commensal-driven immune zonation of the liver promotes host defence. Nature. 2021;589(7840):131-136.  https://doi.org/10.1038/s41586-020-2977-2
  • Kurokawa Y, Honma Y, Sawaki A, Naito Y, Iwagami S, Komatsu Y, Takahashi T, Nishida T, Doi T. Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial. Annals of Oncology. 2022;33(9):959-967.  https://doi.org/10.1016/j.annonc.2022.05.518
  • Du CY, Zhou Y, Song C, Wang YP, Jie ZG, He YL, Liang XB, Cao H, Yan ZS, Shi YQ. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: A prospective randomised trial in China. European Journal of Cancer. 2014;50(10):1772-1778. https://doi.org/10.1016/j.ejca.2014.03.280
  • McAuliffe JC, Hunt KK, Lazar AJ, Choi H, Qiao W, Thall P, Pollock RE, Benjamin RS, Trent JC. A Randomized, Phase II Study of Preoperative plus Postoperative Imatinib in GIST: Evidence of Rapid Radiographic Response and Temporal Induction of Tumor Cell Apoptosis. Annals of Surgical Oncology. 2009;16(4):910-919.  https://doi.org/10.1245/s10434-008-0177-7
  • Corless CL, Ballman KV, Antonescu C, Blanke CD, Blackstein ME, Demetri GD, von Mehren M, Maki RG, Pisters PW, DeMatteo RP. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001. Journal of Clinical Oncology. 2010;28(15 Suppl):10006-10006. https://doi.org/10.1200/jco.2010.28.15_suppl.10006
  • Cousin S. A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE). Accessed August 20, 2024. https://clinicaltrials.gov/study/NCT03475953#more-information
  • Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib. Accessed August 20, 2024. https://clinicaltrials.gov/study/NCT0440922
  • Cogent Biosciences. (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors. Accessed August 20, 2024. https://clinicaltrials.gov/ct2/show/NCT05208047
  • Matsumoto S, Takayama T, Wakatsuki K, Enomoto K, Tanaka T, Migita K, Takano M, Nakajima Y. An esophageal gastrointestinal stromal tumor with regional lymph node metastasis. Esophagus. 2010;7(2):115-118.  https://doi.org/10.1007/s10388-010-0231-y
  • Koyanagi K, Nakagawa M, Ozawa S, Nagase T, Seishima R, Kanai T. Thoracoscopic enucleation for small-sized gastrointestinal stromal tumor of the esophagus: report of two cases. Esophagus. 2010;7(4):219-224.  https://doi.org/10.1007/s10388-010-0243-7
  • Masuda T, Toh Y, Kabashima A, Aoki Y, Harimoto N, Ito S, Taomoto J, Ikeda O, Ohga T, Adachi E, Sakaguchi Y, Hirahashi M, Nishiyama K, Okamura T. Overt lymph node metastases from a gastrointestinal stromal tumor of the esophagus. Journal of Thoracic and Cardiovascular Surgery. 2007;134(3):810-811.  https://doi.org/10.1016/j.jtcvs.2007.06.002
  • Kobayashi H, Kiguchi G, Miki A, Uryuhara K, Okada N, Kaihara S, Imai Y, Hosotani R. A case report of giant esophageal gastrointestinal stromal tumor surgically resected after preoperative imatinib treatment. Esophagus. 2011;8(2):119-124.  https://doi.org/10.1007/s10388-011-0264-x
  • Sato H, Kanda T, Hirota S, Bamba T, Sakamoto K, Kosugi SI, Matsuki A, Mashima Y, Watanabe G, Hatakeyama K. Surgical resection of gastrointestinal stromal tumor of esophagus following preoperative imatinib treatment: a case report. Esophagus. 2010;7(1):65-69.  https://doi.org/10.1007/s10388-009-0217-9
  • Miettinen M, Sobin LH, Lasota J. Gastrointestinal Stromal Tumors of the Stomach. American Journal of Surgical Pathology. 2005;29(1):52-68.  https://doi.org/10.1097/01.pas.0000146010.92933
  • Luo Y, Wu Y, Chang X, Huang B, Luo D, Zhang J, Zhang P, Shi H, Fan J, Nie X. Identification of a novel FGFR2-KIAA1217 fusion in esophageal gastrointestinal stromal tumours: A case report. Frontiers in Oncology. 2022;12.  https://doi.org/10.3389/fonc.2022.884814
  • Haller F, Moskalev EA, Faucz FR, Barthelmeß S, Wiemann S, Bieg M, Assie G, Bertherat J, Schaefer IM, Otto C, Rattenberry E, Maher ER, Ströbel P, Werner M, Carney JA, Hartmann A, Stratakis CA, Agaimy A. Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad. Endocrine-Related Cancer. 2014;21(4):567-577.  https://doi.org/10.1530/ERC-14-0254
  • Zhang L, Smyrk TC, Young WF, Stratakis CA, Carney JA. Gastric Stromal Tumors in Carney Triad Are Different Clinically, Pathologically, and Behaviorally From Sporadic Gastric Gastrointestinal Stromal Tumors: Findings in 104 Cases. American Journal of Surgical Pathology. 2010;34(1):53-64.  https://doi.org/10.1097/PAS.0b013e3181c20f4f
  • Ricci R, Martini M, Cenci T, Carbone A, Lanza P, Biondi A, Rindi G, Cassano A, Larghi A, Persiani R, Larocca LM. PDGFRA-mutant syndrome. Modern Pathology. 2015;28(7):954-964.  https://doi.org/10.1038/modpathol.2015.56
  • Arita A, Takahashi T, Nakajima K, Kurokawa Y, Hirota S, Nishida T, Yamashita K, Saito T, Tanaka K, Makino T, Yamasaki M, Kawai K, Motoyama Y, Morii E, Eguchi H, Doki Y. Surgery for multiple gastric gastrointestinal stromal tumors and large esophageal diverticulum related to germline mutation of the KIT gene: a case report. Surgical Case Reports. 2023;9(1):183.  https://doi.org/10.1186/s40792-023-01766-w
  • Bachet JB, Landi B, Laurent-Puig P, Italiano A, Le Cesne A, Lévy P, Safar V, Duffaud F, Blay JY, Emile JF. Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13. European Journal of Cancer. 2013;49(11):2531-2541. https://doi.org/10.1016/j.ejca.2013.04.005
  • Ohshima K, Fujiya K, Nagashima T, Ohnami S, Hatakeyama K, Urakami K, Naruoka A, Watanabe Y, Moromizato S, Shimoda Y, Ohnami S, Serizawa M, Akiyama Y, Kusuhara M, Mochizuki T, Sugino T, Shiomi A, Tsubosa Y, Uesaka K, Terashima M, Yamaguchi K. Driver gene alterations and activated signaling pathways toward malignant progression of gastrointestinal stromal tumors. Cancer Science. 2019;110(12):3821-3833. https://doi.org/10.1111/cas.14202
  • Joensuu H, Eriksson M, Hall KS, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Ballman KV, Leinonen M, DeMatteo RP, Reichardt P. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. Cancer. 2014;120(15):2325-2333. https://doi.org/10.1002/cncr.28669
  • Rubió-Casadevall J, Borràs JL, Carmona-García MC, Ameijide A, Gonzalez-Vidal A, Ortiz MR, Bosch R, Riu F, Parada D, Martí E, Miró J, Sirvent JJ, Galceran J, Marcos-Gragera R. Correlation between mutational status and survival and second cancer risk assessment in patients with gastrointestinal stromal tumors: a population-based study. World Journal of Surgical Oncology. 2015;13(1):47.  https://doi.org/10.1186/s12957-015-0474-0
  • Joensuu H, Rutkowski P, Nishida T, Steigen SE, Brabec P, Plank L, Nilsson B, Braconi C, Bordoni A, Magnusson MK, Sufliarsky J, Federico M, Jonasson JG, Hostein I, Bringuier PP, Emile JF. KIT and PDGFRA Mutations and the Risk of GI Stromal Tumor Recurrence. Journal of Clinical Oncology. 2015;33(6):634-642.  https://doi.org/10.1200/JCO.2014.57.4970
  • Park JW, Cho CH, Jeong DS, Chae HD. Role of 18F-fluoro-2-deoxyglucose Positron Emission Tomography in Gastric GIST: Predicting Malignant Potential Pre-operatively. Journal of Gastric Cancer. 2011;11(3):173-179.  https://doi.org/10.5230/jgc.2011.11.3.173
  • Dendy M, Johnson K, Boffa DJ. Spectrum of FDG uptake in large (>10 cm) esophageal leiomyomas. Journal of Thoracic Disease. 2015;7(12):E648-E651. https://doi.org/10.3978/j.issn.2072-1439.2015.11.64
  • Săftoiu A. Endoscopic ultrasound-guided fine needle aspiration biopsy for the molecular diagnosis of gastrointestinal stromal tumors: shifting treatment options. Journal of Gastrointestinal and Liver Diseases. 2008;17(2):131-133. 
  • Lott S, Schmieder M, Mayer B, Henne-Bruns D, Knippschild U, Agaimy A, Schwab M, Kramer K. Gastrointestinal stromal tumors of the esophagus: evaluation of a pooled case series regarding clinicopathological features and clinical outcome. American Journal of Cancer Research. 2015;5(1):333-343. 
  • Stelow EB, Stanley MW, Lai R, Mallery S. Endoscopic Ultrasound-Guided Fine-Needle Aspiration Findings of Gastrointestinal Leiomyomas and Gastrointestinal Stromal Tumors. American Journal of Clinical Pathology. 2003;119(5):703-708.  https://doi.org/10.1309/UWUV-Q001-0D9W-0HPN
  • Nemeth K, Williams C, Rashid M, Robinson M, Rasheed A. Oesophageal GIST—A rare breed case report and review of the literature. International Journal of Surgery Case Reports. 2015;10: 256-259.  https://doi.org/10.1016/j.ijscr.2015.02.023
  • Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology. 2008;53(3):245-266.  https://doi.org/10.1111/j.1365-2559.2008.02977.x
  • Gold JS, Gönen M, Gutiérrez A, Broto JM, García-del-Muro X, Smyrk TC, Maki RG, Singer S, Brennan MF, Antonescu CR, Donohue JH, DeMatteo RP. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. The Lancet Oncology. 2009;10(11):1045-1052. https://doi.org/10.1016/S1470-2045(09)70242-6
  • Wozniak A, Rutkowski P, Piskorz A, Ciwoniuk M, Osuch C, Bylina E, Sygut J, Chosia M, Rys J, Urbanczyk K, Kruszewski W, Sowa P, Siedlecki J, Debiec-Rychter M, Limon J; Polish Clinical GIST Registry. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. Annals of Oncology. 2012;23(2):353-360.  https://doi.org/10.1093/annonc/mdr127
  • Yamamoto H, Ebihara Y, Tanaka K, Matsui A, Nakanishi Y, Asano T, Noji T, Kurashima Y, Murakami S, Nakamura T, Tsuchikawa T, Okamura K, Shichinohe T, Hirano S. Robot-assisted thoracoscopic esophagectomy for gastrointestinal stromal tumor of the esophagus: A case report. International Journal of Surgery Case Reports. 2021;86:106335. https://doi.org/10.1016/j.ijscr.2021.106335
  • Marqueen KE, Moshier E, Buckstein M, Ang C. Neoadjuvant therapy for gastrointestinal stromal tumors: A propensity score‐weighted analysis. International Journal of Cancer. 2021;149(1):177-185.  https://doi.org/10.1002/ijc.33536
  • Wang D, Zhang Q, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M, Eisenberg BL. Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132. Annals of Surgical Oncology. 2012;19(4):1074-1080. https://doi.org/10.1245/s10434-011-2190-5
  • Nishida T, Kanda T, Nishitani A, Takahashi T, Nakajima K, Ishikawa T, Hirota S. Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib‐resistant gastrointestinal stromal tumor. Cancer Science. 2008;99(4):799-804.  https://doi.org/10.1111/j.1349-7006.2008.00727.x
  • Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, Brennan MF, Maki RG, DeMatteo RP. Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation. Clinical Cancer Research. 2005;11(11):4182-4190. https://doi.org/10.1158/1078-0432.CCR-04-2245
  • See full prescribing information for VITRAKVI. Accessed September 10, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf
  • US Food and Drug Administration. Prescribing information — Rozlytrek. Accessed September 10, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf
  • Yebra M, Bhargava S, Kumar A, Burgoyne AM, Tang CM, Yoon H, Banerjee S, Aguilera J, Cordes T, Sheth V, Noh S, Ustoy R, Li S, Advani SJ, Corless CL, Heinrich MC, Kurzrock R, Lippman SM, Fanta PT, Harismendy O, Metallo C, Sicklick JK. Establishment of Patient-Derived Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response. Clinical Cancer Research. 2022;28(1):187-200.  https://doi.org/10.1158/1078-0432.CCR-21-2092
  • Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST). Accessed September 10, 2024. https://clinicaltrials.gov/study/NCT03556384
  • Dhillon S. Ripretinib: First Approval. Drugs. 2020;80(11):1133-1138. https://doi.org/10.1007/s40265-020-01348-2
  • See full prescribing information for QINLOCK. Accessed September 10, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf
  • US Food and Drug Administration. FDA approves avapritinib for gastrointestinal stromal tumor with a rare mutation. Accessed September 10, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation
  • Chi P, Qin LX, Nguyen B, Kelly CM, D’Angelo SP, Dickson MA, Gounder MM, Keohan ML, Movva S, Nacev BA, Rosenbaum E, Thornton KA, Crago AM, Yoon S, Ulaner G, Yeh R, Martindale M, Phelan HT, Biniakewitz MD, Warda S, Lee CJ, Berger MF, Schultz ND, Singer S, Hwang S, Chen Y, Antonescu CR, Tap WD. Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. Journal of Clinical Oncology. 2022;40(9):997-1008. https://doi.org/10.1200/JCO.21.02029
  • US National Library of Medicine. A study of pimitespib in combination with imatinib in patients with GIST (CHAPTER-GIST-101). Accessed September 10, 2024. https://www.clinicaltrials.gov/ct2/show/NCT05245968
  • Joensuu H, Blay JY, Comandone A, Martin-Broto J, Fumagalli E, Grignani G, Del Muro XG, Adenis A, Valverde C, Pousa AL, Bouché O, Italiano A, Bauer S, Barone C, Weiss C, Crippa S, Camozzi M, Castellana R, Le Cesne A. Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib. British Journal of Cancer. 2017;117(9):1278-1285. https://doi.org/10.1038/bjc.2017.290
  • Adis insight. Gastrointestinal stromal tumours. Accessed September 10, 2024. https://adisinsight.springer.com/drugs/800063657
  • US National Library of Medicine. A phase I/II study of regorafenib plus avelumab in solid tumors (REGOMUNE). Accessed September 10, 2024. https://clinicaltrials.gov/ct2/show/NCT03475953
  • US National Library of Medicine. PDR001 plus imatinib for metastatic or unresectable GIST. Accessed September 10, 2024. https://clinicaltrials.gov/ct2/show/NCT03609424
  • Call J, Walentas C, Eickhoff JC, Scherzer N. Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry. BMC Cancer. 2012;12(1):90.  https://doi.org/10.1186/1471-2407-12-90
  • Miettinen M, Lasota J. Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Seminars in Diagnostic Pathology. 2006;23(2):70-83.  https://doi.org/10.1053/j.semdp.2006.09.001
  • IJzerman NS, van Werkhoven E, Mohammadi M, Hollander DD, Bleckman RF, Reyners AKL, Desar IME, Gelderblom H, Grünhagen DJ, Mathijssen RHJ, Steeghs N, van der Graaf WTA. Sex differences in patients with gastrointestinal stromal tumours: do they exist and does it affect survival? ESMO Open. 2022;7(6):100649. https://doi.org/10.1016/j.esmoop.2022.100649
  • Volchenko NS, Mamontov AS, Goeva NS. Rare esophageal tumors. Onkologiya. P.A. Herzen Journal of Oncology. 2019;8(6):453.  https://doi.org/10.17116/onkolog20198061453
  • Cohen C, Pop D, Icard P, Berthet JP, Venissac N, Mouroux J. Is There a Place for Thoracoscopic Enucleation of Esophageal Gastrointestinal Stromal Tumors? The Thoracic and Cardiovascular Surgeon. 2019;67(07):585-588.  https://doi.org/10.1055/s-0038-1670662
  • Keung EZ, Raut CP. Management of Gastrointestinal Stromal Tumors. Surgical Clinics of North America. 2017;97(2):437-452.  https://doi.org/10.1016/j.suc.2016.12.001
  • Gronchi A, Raut CP. The Combination of Surgery and Imatinib in GIST: A Reality for Localized Tumors at High Risk, an Open Issue for Metastatic Ones. Annals of Surgical Oncology. 2012;19(4): 1051-1055. https://doi.org/10.1245/s10434-011-2191-4
  • Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, Fletcher CD, Demetri GD, Bertagnolli MM. Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment With Targeted Systemic Therapy Using Kinase Inhibitors. Journal of Clinical Oncology. 2006;24(15):2325-2331. https://doi.org/10.1200/JCO.2005.05.3439
  • Blackstein ME, Blay JY, Corless C, Driman DK, Riddell R, Soulières D, Swallow CJ, Verma S; Canadian Advisory Committee on GIST. Gastrointestinal Stromal Tumours: Consensus Statement on Diagnosis and Treatment. Canadian Journal of Gastroenterology. 2006;20(3):157-163.  https://doi.org/10.1155/2006/434761
  • DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR. Results of Tyrosine Kinase Inhibitor Therapy Followed by Surgical Resection for Metastatic Gastrointestinal Stromal Tumor. Annals of Surgery. 2007;245(3):347-352.  https://doi.org/10.1097/01.sla.0000236630.93587.59
  • Klug LR, Khosroyani HM, Kent JD, Heinrich MC. New treatment strategies for advanced-stage gastrointestinal stromal tumours. Nature Reviews Clinical Oncology. 2022;19(5):328-341.  https://doi.org/10.1038/s41571-022-00606-4
  • A phase 1, multicenter, open-label, first-in-human study of DS-6157a in patients (pts) with advanced gastrointestinal stromal tumor (GIST). Accessed September 10, 2024. https://meetings.asco.org/abstracts-presentations/208008
  • DS-6157a in Participants with Advanced Gastrointestinal Stromal Tumor (GIST). Accessed September 10, 2024. https://clinicaltrials.gov/ct2/show/NCT04276415
    • Contact the author
    Email
    Message
    The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

    Email Confirmation

    An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

    Email Confirmation

    Submit Application

    You can become an author of one of our magazines, send a request and we will consider it in during the day.

    Name
    Phone
    E-mail
    Message
    Login
    Registration
    E-mail
    Password
    Forgot Password?

    Log in to the site using your account in one of the services

    Password recovery
    E-mail
    Login
    Register

    We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.